APA (7th ed.) Citation

Gale, D., Heider, K., Ruiz-Valdepenas, A., Hackinger, S., Perry, M., Marsico, G., . . . Rassl, D. (2022). Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Annals of Oncology, 33(5), 500. https://doi.org/10.1016/j.annonc.2022.02.007

Chicago Style (17th ed.) Citation

Gale, D., et al. "Residual CtDNA After Treatment Predicts Early Relapse in Patients with Early-stage Non-small Cell Lung Cancer." Annals of Oncology 33, no. 5 (2022): 500. https://doi.org/10.1016/j.annonc.2022.02.007.

MLA (9th ed.) Citation

Gale, D., et al. "Residual CtDNA After Treatment Predicts Early Relapse in Patients with Early-stage Non-small Cell Lung Cancer." Annals of Oncology, vol. 33, no. 5, 2022, p. 500, https://doi.org/10.1016/j.annonc.2022.02.007.